Search research articles
Contact Us
Filters
Showing results (251-260 of 296) with videos related to
Page
of 30
Sort By:
Clinical Pharmacokinetics
|
May 17, 2017
Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers
Kevinkumar A Kansagra, Deven Parmar, Rajendra H Jani, et al.
ESMO Open
|
April 20, 2024
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
T Powles, M Burotto, B Escudier, et al.
Urologic Oncology
|
August 12, 2022
Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma
Craig V Labbate, Patrick J Hensley, Tanner S Miest, et al.
BJU International
|
July 6, 2021
Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation
Brian De, Aradhana M Venkatesan, Pavlos Msaouel, et al.
Urologic Oncology
|
November 14, 2020
Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors
Jad Chahoud, Pavlos Msaouel, Jeremy A Ross, et al.
NPJ Precision Oncology
|
April 18, 2023
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
Omar Alhalabi, Roman Groisberg, Ralph Zinner, et al.
European Urology Oncology
|
December 2, 2019
Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors
Jeffrey Graham, Amishi Y Shah, J Connor Wells, et al.
Journal for Immunotherapy of Cancer
|
March 3, 2026
Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma
Kabir Grewal, Maria Julia Moura Nascimento Santos, Pankaj Kumar Chauhan, et al.
Journal of Vascular and Interventional Radiology : JVIR
|
May 19, 2026
Stereotactic Percutaneous Thermal Ablation of Primary and Metastatic Liver Tumors: A Prospective Registry-Based Study
Iwan Paolucci, Jessica Albuquerque, Noreen S Siddiqi, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 29, 2022
Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience
Marilyne Daher, Jeena Varghese, Stephen K Gruschkus, et al.
Page
of 30
Search research articles
Search
Showing results (251-260 of 296) with videos related to
Sort By:
Page
of 30
Clinical Pharmacokinetics
|
May 17, 2017
Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers
Kevinkumar A Kansagra, Deven Parmar, Rajendra H Jani, et al.
ESMO Open
|
April 20, 2024
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
T Powles, M Burotto, B Escudier, et al.
Urologic Oncology
|
August 12, 2022
Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma
Craig V Labbate, Patrick J Hensley, Tanner S Miest, et al.
BJU International
|
July 6, 2021
Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation
Brian De, Aradhana M Venkatesan, Pavlos Msaouel, et al.
Urologic Oncology
|
November 14, 2020
Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors
Jad Chahoud, Pavlos Msaouel, Jeremy A Ross, et al.
NPJ Precision Oncology
|
April 18, 2023
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
Omar Alhalabi, Roman Groisberg, Ralph Zinner, et al.
European Urology Oncology
|
December 2, 2019
Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors
Jeffrey Graham, Amishi Y Shah, J Connor Wells, et al.
Journal for Immunotherapy of Cancer
|
March 3, 2026
Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma
Kabir Grewal, Maria Julia Moura Nascimento Santos, Pankaj Kumar Chauhan, et al.
Journal of Vascular and Interventional Radiology : JVIR
|
May 19, 2026
Stereotactic Percutaneous Thermal Ablation of Primary and Metastatic Liver Tumors: A Prospective Registry-Based Study
Iwan Paolucci, Jessica Albuquerque, Noreen S Siddiqi, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 29, 2022
Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience
Marilyne Daher, Jeena Varghese, Stephen K Gruschkus, et al.
Page
of 30